Supplement Encapsulation, Coating and Delayed-Release Technology Playbook

Enteric coating protects the active ingredient through the acidic gastric environment (pH 1-3) for release in the small intestine (pH 6-7), used in supplements where the active is gastric-acid-degraded (probiotics, enzyme preparations) or where the dosage form releases unpleasant character (fish oil burp-back). Polymer systems include methacrylic acid copolymers (Eudragit L, S, FS series), hypromellose phthalate (HPMCP), hypromellose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP) and polyvinyl acetate phthalate (PVAP). Each polymer has a defined dissolution pH threshold — Eudragit L 100 dissolves at pH ≥6.0, L 100-55 at pH ≥5.5, S 100 at pH ≥7.0 — driving the choice based on target release site (proximal small intestine vs distal). USP <2040> Disintegration and Dissolution of Dietary Supplements defines the test method for delayed-release dietary supplements with 2 hours in 0.1 N HCl (acid stage) followed by buffer stage at the appropriate pH; acceptance criteria require minimal acid-stage release (typically <10%) and adequate buffer-stage release (typically >75% within 45-60 minutes). Validation must demonstrate the coating performs across batch variation, scale-up, accelerated stability, ambient stability and end-of-shelf-life conditions. Enteric coating failures — coating cracks, uneven application, polymer interaction with capsule shell — are common and require process control of coating-bed temperature, spray rate, atomisation, drying and curing.

Microencapsulation encloses individual active particles in a polymer or lipid coating at micrometre scale, used for oxidation protection (omega-3, vitamin C, polyphenols), flavour masking (B vitamins, taurine, iron), controlled release (caffeine, melatonin) and incompatible-actives separation (iron and vitamin C, calcium and iron). Process platforms include spray drying (atomisation of an emulsion or solution through a drying chamber producing micron-scale particles with the active encapsulated within the matrix material), fluid-bed coating (suspension of seed particles in an upward gas flow with coating polymer sprayed onto the moving particles), coacervation (phase-separation precipitation of a coating polymer around a dispersed active), and emulsion solidification. Matrix materials include gum arabic, modified starch, maltodextrin, gelatin, chitosan, alginate, whey protein, lipid systems (glyceryl monostearate, hydrogenated vegetable oil, beeswax) and biodegradable polymers. Quality control includes particle size distribution (laser diffraction), encapsulation efficiency (measurement of free vs encapsulated active), release profile (in vitro dissolution under target conditions), stability of the encapsulation across shelf life, and identity preservation of the active through the encapsulation process. Microencapsulation claims on label (e.g. 'microencapsulated for slow release') must be supported by validated release-profile evidence, not asserted on the manufacturing-process basis alone.

Liposomal delivery uses phospholipid vesicles (typically derived from soy, sunflower or egg lecithin) to encapsulate water-soluble actives within the aqueous core and lipid-soluble actives within the lipid bilayer, with claimed benefits including improved bioavailability, gastrointestinal tolerability and targeted cellular delivery. Liposomal supplement formats are common for vitamin C, glutathione, vitamin D, vitamin K, B complex, NMN/NAD+ precursors, CoQ10 and several other actives. The category has been subject to FDA Warning Letter activity and class-action litigation around (1) actual liposomal structure — many products marketed as liposomal are simple oil-in-water emulsions or micelle systems without verified phospholipid bilayer vesicles, (2) bioavailability claims — comparative bioavailability claims (e.g. '5x better absorption') require head-to-head pharmacokinetic study evidence against the reference dosage form, (3) particle size — true liposomes are typically 50-500 nm with verified vesicle structure under cryo-electron microscopy or dynamic light scattering, distinguished from emulsion droplets that may be larger and lack bilayer structure. Defensible liposomal claims require characterised vesicle structure with appropriate analytical evidence (cryo-EM, DLS, NMR, encapsulation efficiency), bioavailability evidence supporting comparative claims, and stability of the vesicle structure across shelf life and gastric exposure. The 'liposomal' label claim without substantiating vesicle evidence is a recurring high-visibility compliance and reputational failure.

Sustained-release matrix systems use hydrophilic polymers (hypromellose, sodium alginate, xanthan gum, sodium carboxymethylcellulose) or hydrophobic matrices (waxes, hydrogenated vegetable oils, ethylcellulose) to slow active dissolution and provide extended plasma concentration profiles. Common supplement applications include sustained-release caffeine (smoothing the typical peak-and-crash profile), sustained-release B vitamins (extending the limited absorption window), sustained-release iron (improving tolerability by reducing peak gastric concentration that drives nausea and constipation), and sustained-release melatonin (matching the natural circadian profile). Dissolution profile validation per USP <2040> at multiple time points (1, 2, 4, 8, 12, 24 hours depending on the target profile) with discriminating method development is essential — the dissolution method must distinguish a successful sustained-release formulation from an immediate-release control. Bioavailability validation may be required for label claims around extended duration, smoother plasma profile or improved tolerability. Manufacturing controls cover polymer/wax specification consistency, granulation or coating process parameters, tablet hardness and friability for matrix integrity, and ongoing dissolution profile monitoring.

Manufacturing controls for encapsulation, coating and modified-release dosage forms include (1) raw material specification and supplier qualification for coating polymers, lipids, phospholipids and matrix materials with lot-by-lot consistency monitoring; (2) process parameter control with documented validation of critical process parameters and ongoing trend monitoring (coating-bed temperature, spray rate, atomisation pressure, drying temperature and time, curing conditions); (3) in-process controls including coating weight gain or thickness, particle size for spray-dried microcapsules, granule size distribution; (4) finished-product release including dissolution per USP <2040> at appropriate conditions, content uniformity per USP <905>, identity and assay; (5) stability including dissolution profile across shelf life (modified-release dissolution often drifts due to polymer ageing); (6) label-claim substantiation per the relevant FTC competent-and-reliable-scientific-evidence standard, with specific attention to liposomal, bioavailability, slow-release and targeted-delivery claims that have been subject to historical enforcement action. Post-market validation includes adverse event monitoring for unexpected pharmacokinetic profile (sustained-release iron dose dumping, enteric-coated probiotic failure to deliver viable organisms), platform compliance monitoring (Amazon, retailer and certification programmes have raised technology-claim substantiation expectations) and competitor analysis for technology-claim drift in the category.